Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-OGA Antibody (R1E63)

Catalog #:   RHA92901 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IHC, IP, WB
Accession: O60502
Overview

Catalog No.

RHA92901

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IHC: 1:100-1:200, IP: 1:20-1:50, WB: 1:1000-1:2000

Target

OGA, Protein O-GlcNAcase, Meningioma-expressed antigen 5, Beta-N-acetylhexosaminidase, HEXC, N-acetyl-beta-glucosaminidase, KIAA0679, Nuclear cytoplasmic O-GlcNAcase and acetyltransferase, MEA5, MGEA5, Beta-hexosaminidase, NCOAT, Beta-N-acetylglucosaminidase, N-acetyl-beta-D-glucosaminidase

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

O60502

Applications

IHC, IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R1E63

Data Image
  • Western blot
    All lanes use the Antibody at 1:500 dilution for 1 hour at room temperature.
  • Western blot
    Western blot analysis of MGEA5 expression in JAR cell lysate.
References

Expression of O-GlcNAcylation in pulp tissue and dental pulp stem cells of healthy dental organs., PMID:40152124

HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC., PMID:39853458

A case of MSI-high pancreatic body-tail cancer successfully treated with radical resection after pembrolizumab., PMID:39402396

O-GlcNAcylation of ribosome-associated proteins is concomitant with translational reprogramming during proteotoxic stress., PMID:39395807

A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies., PMID:39381863

Systematic Evaluation of Affinity Enrichment Methods for O-GlcNAc Proteomics., PMID:39302247

Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer., PMID:38964205

Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE., PMID:38518549

Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge., PMID:38444344

Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis., PMID:38184565

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study., PMID:37940383

Human schistosomiasis in Nigeria: present status, diagnosis, chemotherapy, and herbal medicines., PMID:37851179

Malocclusion impairs cognitive behavior via AgRP signaling in adolescent mice., PMID:37168929

Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study., PMID:36881202

A novel shark single-domain antibody targeting OGT as a tool for detection and intracellular localization., PMID:36855630

Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers., PMID:36642483

Ac34FGlcNAz is an effective metabolic chemical reporter for O-GlcNAcylated proteins with decreased S-glyco-modification., PMID:36610251

Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis., PMID:36446578

Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development., PMID:36350330

IgG4-related lung disease with multifocal pulmonary consolidations near the pleura: A case report., PMID:36042602

Dry preserved multilayered fibroblast cell sheets are a new manageable tool for regenerative medicine to promote wound healing., PMID:35869108

Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease., PMID:35618441

CD44 is critical for the enhancing effect of hyaluronan in allergen-specific sublingual immunotherapy in a murine model of chronic asthma., PMID:35429379

Vaginal delivery after improvement in COVID-19 by monoclonal antibody treatment: A case report and literature review., PMID:35288022

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial., PMID:34800399

The Metabolic Chemical Reporter Ac46AzGal Could Incorporate Intracellular Protein Modification in the Form of UDP-6AzGlc Mediated by OGT and Enzymes in the Leloir Pathway., PMID:34712646

O-GlcNAcylation Quantification of Certain Protein by the Proximity Ligation Assay and Clostridium perfringen OGAD298N(CpOGAD298N)., PMID:34105348

A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer., PMID:33865813

New Insights Into the Biology of Protein O-GlcNAcylation: Approaches and Observations., PMID:35822169

Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase., PMID:33686291

The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome., PMID:33258073

An unusual but unmissable link between summer-type hypersensitivity pneumonitis and asthma in an old house., PMID:32695568

Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases., PMID:32514165

Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(®)) in immunodeficiency diseases: real-life data from a monocentric experience., PMID:32385734

O-GlcNAcylation of light chain serine 12 mediates rituximab production doubled by thiamet G., PMID:31980903

Comparison of hepatitis B vaccine efficacy in Japanese students: a retrospective study., PMID:31878867

Thoracoscopic Findings in IgG4-related Pleuritis., PMID:31554752

Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma., PMID:31538325

A Chemical Genetic Method for Monitoring Genome-Wide Dynamics of O-GlcNAc Turnover on Chromatin-Associated Proteins., PMID:31041386

Ac4GlcNAcF3, an OGT-tolerated but OGA-resistant regulator for O-GlcNAcylation., PMID:30713024

Production of Glycopeptide Derivatives for Exploring Substrate Specificity of Human OGA Toward Sugar Moiety., PMID:30693278

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study., PMID:30510079

A case report of pregnancy in a patient with common variable immunodeficiency emphasizing the need for personalized immunoglobulin replacement., PMID:30383634

Detecting and Imaging O-GlcNAc Sites Using Glycosyltransferases: A Systematic Approach to Study O-GlcNAc., PMID:30100348

[An eye for an eye? Lack of consensus in off-label use of medications leads to major regional differences in medical costs for the treatment of wet AMD in Sweden]., PMID:29292948

Facilitated Subcutaneous Immunoglobulin (fSCIg) in Autoimmune Cytopenias Associated with Common Variable Immunodeficiency., PMID:28786256

Characterization of tools to detect and enrich human and mouse O-GlcNAcase., PMID:28595377

The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies., PMID:28461123

Fatty acid synthase inhibits the O-GlcNAcase during oxidative stress., PMID:28232487

The Nuts and Bolts of Immunoglobulin Treatment for Antibody Deficiency., PMID:27836057

Datasheet

Document Download

Anti-OGA Antibody (R1E63).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-OGA Antibody (R1E63) [RHA92901]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only